The delisting risk is acute and the company has no standard compliance path due to the prior reverse split. Monitor for the Nasdaq Hearings Panel decision timeline and any further capital raise or reverse split attempt. The recent $250M ATM offering suggests the company may attempt to raise additional dilutive capital, which would further pressure the stock.
Price Chart
Executive Summary
KALA BIO received a delisting notice from Nasdaq on August 27, 2026, because its stock closed below $1.00 for 30 consecutive business days. The company is ineligible for the standard 180-day compliance period because it already executed a 1-for-50 reverse stock split on May 11, 2026. KALA intends to appeal to a Nasdaq Hearings Panel, which will stay any suspension pending a decision, but the path to regaining compliance is highly uncertain given the company's distressed financial condition and recent massive ATM equity offering.
Key Facts
- Nasdaq notified KALA on August 27, 2026 that its bid price was below $1.00 for 30 consecutive business days (July 16–August 26, 2026).
- KALA is ineligible for the standard 180-day compliance period because it effected a 1-for-50 reverse stock split on May 11, 2026.
- KALA intends to request a hearing before the Nasdaq Hearings Panel to appeal the delisting determination.
- A timely hearing request will stay any suspension or delisting action pending the Panel's decision.
- The company previously filed a 424B5 on July 22, 2026 for an ATM offering of up to $250M in common stock, signaling severe financial distress.
Financial Impact
Potential total loss of Nasdaq listing, severely reducing institutional ownership and liquidity for a $16M market cap company with no revenue and no ongoing clinical trials.
Risk Factors
- Nasdaq Hearings Panel may deny continued listing or impose conditions KALA cannot meet
- No standard 180-day compliance cure period available due to prior reverse split
- Company has no revenue and no ongoing clinical trials, making a fundamental turnaround unlikely
- Massive potential dilution from the $250M ATM offering could further depress the stock price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-009454 |
| Document: 0001829126-26-009454-index.html | 0001829126-26-009454 |
| Document: 0001829126-26-009454.txt | 0001829126-26-009454 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 5w ago | 8-K | $0.6901 $0.4502 | ▲ +34.76% | ▲ +35.02% | $0.3884 (+43.72%) |
Jul 22, 2026 10w ago | 424B5 | $0.6103 $0.8401 | ▼ −37.65% | ▼ −34.35% | $0.3884 (+36.36%) |
Jun 26, 2026 14w ago | EFFECT | $2.52 $0.6103 | ▲ +75.78% | ▲ +77.04% | $0.3884 (+84.59%) |
May 7, 2026 21w ago | S-3 | $3.95 $2.06 | ▼ −47.85% | ▼ −47.87% | $0.3884 (−90.17%) |
Mar 4, 2026 30w ago | Press Release | $17.25 $0.1630 | ▼ −99.06% | ▼ −94.64% | $0.3884 (−97.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access